Stephens Investment Management Group LLC Boosts Holdings in IDEXX Laboratories, Inc. $IDXX

Stephens Investment Management Group LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 97,382 shares of the company’s stock after purchasing an additional 1,781 shares during the quarter. Stephens Investment Management Group LLC’s holdings in IDEXX Laboratories were worth $65,882,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in IDEXX Laboratories by 0.9% in the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after purchasing an additional 86,040 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after purchasing an additional 605,290 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after purchasing an additional 1,442,174 shares during the last quarter. Invesco Ltd. boosted its holdings in IDEXX Laboratories by 14.0% in the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock valued at $843,503,000 after purchasing an additional 161,782 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 34,612 shares of company stock worth $22,525,070 in the last quarter. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Trading Down 0.8%

Shares of IDEXX Laboratories stock opened at $528.79 on Friday. The firm has a 50-day simple moving average of $572.08 and a two-hundred day simple moving average of $645.56. The company has a market cap of $41.71 billion, a P/E ratio of 38.94, a price-to-earnings-growth ratio of 3.07 and a beta of 1.58. IDEXX Laboratories, Inc. has a fifty-two week low of $496.61 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. Piper Sandler lowered their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Barclays decreased their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.